<DOC>
	<DOC>NCT03028480</DOC>
	<brief_summary>This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC). In this study the information regarding the safety and effectiveness of long term use of NUCALA after subcutaneous injection will be collected from Asthma subjects in daily clinical practice. The observation period per subject will be 52 weeks from the initiation of NUCALA treatment with follow-up investigation for 2 years after the observation period. NUCALA is a registered trademark of the GlaxoSmithKline [GSK] group of companies</brief_summary>
	<brief_title>Long Term Special Drug Use Investigation of Mepolizumab</brief_title>
	<detailed_description />
	<criteria>Subjects receiving NUCALA for the first time for treatment of bronchial asthma (a refractory asthma whose symptoms are inadequately controlled despite receiving standard asthma medications) No exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Exacerbation</keyword>
	<keyword>Mepolizumab</keyword>
	<keyword>NUCALA</keyword>
</DOC>